Sino Biopharmaceutical's Earnings Outlook Brighter on Higher Margins -- Market Talk

Dow Jones

08/19

0605 GMT - Sino Biopharmaceutical Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. (jiahui.huang@wsj.com; @ivy_jiahuihuang)

(END) Dow Jones Newswires

August 19, 2025 02:05 ET (06:05 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2560157702"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560157702\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560157702?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 14:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560157702","market":"sh","top_or_hot":-1,"title":"Sino Biopharmaceutical's Earnings Outlook Brighter on Higher Margins -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0605 GMT - <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 19, 2025 02:05 ET (06:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical's Earnings Outlook Brighter on Higher Margins -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical's Earnings Outlook Brighter on Higher Margins -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-08-19 14:05</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0605 GMT - <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 19, 2025 02:05 ET (06:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中國生物製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2560157702","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560157702","pubTimestamp":1755583500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0605 GMT - Sino Biopharmaceutical Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"中国生物制药盈利前景因利润率上升而更加光明——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"0605 GMT - Sino Biopharmaceutical Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 19, 2025 02:05 ET (06:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}